Topical BCX-34 data

BCRX (Birmingham, Ala.) announced Phase II findings of safety and efficacy with concentrations ranging from 0.1 to 5 percent.

After a six-week treatment, a scoring of relevant symptoms showed more than a 50 percent improvement of lesions, statistically significant for both trials (p<0.0001 in the psoriasis trial, and p<0.0184 in the lymphoma trial). The trials enrolled 40 patients with psoriasis and 30 with the lymphoma. ...